Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Open-Label Phase III Trial of Pembrolizumab Versus Platinum Based Chemotherapy in 1L Subjects With PD-L1 Strong Metastatic Non-Small Cell Lung Cancer
Brief Summary: This is a study to assess the efficacy and safety of pembrolizumab (MK-3475/SCH 900475) compared to standard of care (SOC) platinum-based chemotherapies in the treatment of participants with previously untreated stage IV, programmed cell death ligand 1 (PD-L1) strong expressing Non-Small Cell Lung Cancer (NSCLC). The primary hypothesis of this study is that participants with PD-L1 strong NSCLC will have a longer Progression Free Survival (PFS), as assessed by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) when treated with pembrolizumab than when treated with SOC platinum-based chemotherapies.

With Amendment 09 (20 December 2017), once participants have achieved the study objective or the study has ended, participants will be discontinued from this study and enrolled in an extension study to continue protocol-defined assessments and treatment.


Options:
A: Arm Label: pemetrexed + cisplatin followed by pemetrexed; Type: EXPERIMENTAL; Interventions: Drug: Pemetrexed, Drug: Cisplatin, Other: Best Supportive Care | Arm Label: pemetrexed + cisplatin followed by placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Pemetrexed, Drug: Cisplatin, Drug: Placebo, Other: Best Supportive Care | Intervention Type: DRUG; Name: Pemetrexed; Assigned to Arm(s): pemetrexed + cisplatin followed by pemetrexed, pemetrexed + cisplatin followed by placebo | Intervention Type: DRUG; Name: Cisplatin; Assigned to Arm(s): pemetrexed + cisplatin followed by pemetrexed, pemetrexed + cisplatin followed by placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): pemetrexed + cisplatin followed by placebo | Intervention Type: DRUG; Name: Pemetrexed; Assigned to Arm(s): pemetrexed + cisplatin followed by pemetrexed | Intervention Type: OTHER; Name: Best Supportive Care; Assigned to Arm(s): pemetrexed + cisplatin followed by pemetrexed, pemetrexed + cisplatin followed by placebo
B: Arm Label: Pembrolizumab; Type: EXPERIMENTAL; Interventions: Drug: Pembrolizumab | Arm Label: Paclitaxel+Carboplatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Paclitaxel, Drug: Carboplatin, Drug: Pemetrexed | Arm Label: Pemetrexed+Carboplatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carboplatin, Drug: Pemetrexed | Arm Label: Pemetrexed+Cisplatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pemetrexed, Drug: Cisplatin | Arm Label: Gemcitabine+Carboplatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carboplatin, Drug: Gemcitabine | Arm Label: Gemcitabine+Cisplatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Cisplatin, Drug: Gemcitabine | Intervention Type: DRUG; Name: Pembrolizumab; Assigned to Arm(s): Pembrolizumab | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Paclitaxel+Carboplatin | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Gemcitabine+Carboplatin, Paclitaxel+Carboplatin, Pemetrexed+Carboplatin | Intervention Type: DRUG; Name: Pemetrexed; Assigned to Arm(s): Paclitaxel+Carboplatin, Pemetrexed+Carboplatin, Pemetrexed+Cisplatin | Intervention Type: DRUG; Name: Cisplatin; Assigned to Arm(s): Gemcitabine+Cisplatin, Pemetrexed+Cisplatin | Intervention Type: DRUG; Name: Gemcitabine; Assigned to Arm(s): Gemcitabine+Carboplatin, Gemcitabine+Cisplatin
C: Arm Label: Arm A: Nivolumab; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab | Arm Label: Arm B: Docetaxel; Type: ACTIVE_COMPARATOR; Interventions: Drug: Docetaxel | Intervention Type: BIOLOGICAL; Name: Nivolumab; Assigned to Arm(s): Arm A: Nivolumab | Intervention Type: DRUG; Name: Docetaxel; Assigned to Arm(s): Arm B: Docetaxel
D: Arm Label: Dose Escalation; Type: EXPERIMENTAL; Interventions: Drug: MEDI4736, Drug: Tremelimumab | Arm Label: Arm A; Type: EXPERIMENTAL; Interventions: Drug: MEDI4736, Drug: Tremelimumab | Arm Label: Arm B; Type: EXPERIMENTAL; Interventions: Drug: MEDI4736, Drug: tremelimumab | Arm Label: Arm C; Type: EXPERIMENTAL; Interventions: Drug: MEDI4736, Drug: tremelimumab | Intervention Type: DRUG; Name: MEDI4736; Assigned to Arm(s): Arm A, Arm B, Arm C, Dose Escalation | Intervention Type: DRUG; Name: Tremelimumab; Assigned to Arm(s): Arm A, Dose Escalation | Intervention Type: DRUG; Name: tremelimumab; Assigned to Arm(s): Arm B, Arm C

Answer: B